XOMA

XOMA Corporation (XOMA) | Rumor.io

XOMA

Attention (50-day avg)0%

Attention rank (50-day avg)#3,968

Bullish sentiment (50-day avg)96%

Price to earnings ratio25.6

Market capitalization710.2M

Earnings per share1.57

Dividend yield (TTM)5.37%

Revenue (annual)11.7M

Net income (annual)31.7M

Social

What share of all stock conversation is about XOMA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Apr 27

Ligand Pharmaceuticals ($LGND) is acquiring XOMA Royalty Corporation ($XOMA) for approximately $739 million in cash, with XOMA shareholders receiving $39 per share.
The deal will add seven commercial products to Ligand's royalty portfolio, as well as over 120 commercial, clinical, and preclinical assets.
The acquisition will strengthen Ligand's position as a leading biopharma royalty aggregator and further accelerate its profit growth.

Generated by AI

Sentiment

Of the messages about XOMA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% new	92.62% +16.35
Bearish	—	—	0% -100	7.38% -16.35

Bullish· Sep 6

XOMA has shown significant price gains, increasing by 147% since the S&P 500, with a 45% increase in the past day alone.
The company has a low float and a high number of short positions, indicating potential for further price appreciation.
XOMA has received an analyst upgrade to a "Buy" recommendation, suggesting increased confidence in the company's prospects.

Bearish· Mar 8

$XOMA's recent price drop may be due to a $300M shelf offering.
The company's earnings have been unimpressive, with a forecast EPS downgraded to a loss of $-0.42.
$XOMA's price has reached a 100% Fibonacci retracement from its 52-week high, indicating a potential reversal.

Generated by AI

Topics

Of the messages about XOMA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	93.84%
Analysts	—	—	—	2.05%
Controversies	—	—	—	3.23%
Earnings	—	—	—	0.29%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0.59%

Earnings· Mar 9

$XOMA reported Q4 earnings of 21 cents per share, beating analysts' expectations of a 15 cents per share loss.
Revenue was $48.18M, a 1007.6% year-over-year increase that also exceeded expectations.
The company's earnings beat estimate by 36 cents per share and revenue estimate by $44.17M.

Analysts· Sep 5

Wedbush upgraded XOMA Royalty Corp. from Neutral to Outperform with a price target of $19.00.
The price target was raised from $9.00, indicating a significant increase in the analyst's confidence in the company's prospects.
The upgrade is attributed to a pact with Novartis, which validates XOMA's new business model, according to the analyst.

Announcements· Apr 27

Ligand Pharmaceuticals ($LGND) is acquiring XOMA Royalty ($XOMA) in an all-cash deal worth approximately $740 million, or $39 per share.
The acquisition adds royalty exposure to over 120 drugs and expands Ligand's total portfolio to more than 200 medicines and pipeline assets.
XOMA Royalty stockholders will receive $39 per share in cash, representing a premium of 2.9% from the stock's last close, and one non-transferable CVR per share.

Technical Analysis· Mar 10

A MACD buy signal has been triggered on the daily and weekly charts for $XOMA.
$XOMA has formed a base and is expected to continue upwards, with a potential retest of the low.
The chart for $XOMA is showing a reverse head and shoulders pattern, with a potential break above $1.10.

Generated by AI

Community

Of the messages about XOMA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	40%	29.83%
Newcomers	—	—	60%	70.17%

Regulars· Sep 24

The regulars are comparing $XOMA to $TSLA, stating that XOMA has a stronger short-term outlook, with the potential for $TSLA to drop below $300.
Major shareholders, including Value Fund L.P. and Bvf Partners L.P./Il, are acquiring significant shares of XOMA Corp, with Value Fund L.P. buying 51,368 shares and Bvf Partners L.P./Il acquiring 22,328 shares.
The regulars are noting insider buying activity, with a director of XOMA Corp buying 17,089 shares, and one of the regulars estimating that the company's value has a negative long-term outlook.

Newcomers· Apr 27

The buyout of XOMA Royalty Corp. by Ligand Pharmaceuticals is a significant deal, with Ligand agreeing to pay $39 per share for the company, totaling $740 million.
Newcomers to XOMA are treating the stock as a "lotto play" due to its potential for a 5x increase, but also considering it a high-risk investment due to its low price.
The acquisition of XOMA by Ligand is expected to further accelerate profit growth and strengthen Ligand's position as a leading biopharma royalty aggregator, with the deal providing Ligand with royalty exposure to over 120 assets.

Generated by AI

On August 6, Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results showing royalty revenue up 32% year over year, just weeks after the company closed its acquisition of XOMA Royalty. Total revenue reached $63.7 million for the quarter, up from $47.6 million a year earlier, and Ligand raised the low end of its full-year adjusted earnings […]

26d agofinance.yahoo.com

LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) today announced a reminder to...

1mo agoBarchart.com

Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital

Ligand Pharmaceuticals (NASDAQ:LGND) outlined its royalty-focused growth strategy, recent XOMA acquisition and portfolio catalysts during a company presentation, highlighting a larger commercial-stage asset base and planned investment capacity. Chief Financial Officer Tavo Espinoza said Ligand has

1mo agoYahoo Finance

Also Discussed

Investors talking about XOMA also mention

#	Name	Attention
1	Net Element IncNETE	0%0
2	Can-Fite BioPharma Ltd. ADRCANF	0%0
3	BDSI - BioDelivery Sciences International, Inc.	——
4	AEZS - Aeterna Zentaris Inc.	——
5	SUNation Energy Inc.SUNE	0%new
6	Exelixis Inc.EXEL	0%-0.03
7	CTIC - CTI BioPharma Corp.	——
8	FOLD - Amicus Therapeutics, Inc.	——
9	GENE - Genetic Technologies Limited	——
10	MannKind CorporationMNKD	0.02%+0.01

XOMA Corporation

Healthcare
Biotechnology

XOMA Corporation operates as a biotech royalty aggregator, acquiring economic rights to future milestone and royalty payments from pre-commercial clinical candidates and commercial therapies licensed to pharmaceutical and biotechnology companies. This model provides sellers with non-dilutive, non-recourse funding to advance drug development or for general corporate purposes, while XOMA Royalty builds a diversified portfolio spanning multiple therapeutic areas and development stages. The company focuses on development-stage assets with significant commercial potential, partnered with well-capitalized entities, including royalties on marketed products and clinical programs. XOMA Corporation also engages in transactions with distressed biotechs, acquiring and monetizing their intellectual property to generate returns. With over 120 assets, it plays a key role in the biotech financing ecosystem by bridging funding gaps and supporting innovation in human health therapies across regions including the United States, Europe, and Asia Pacific. Founded in 1981 and headquartered in Emeryville, California, XOMA Corporation maintains a lean operation dedicated to royalty aggregation.

Website

Location

2200 Powell Street

EmeryVille, CA, 94608

United States

Social

What share of all stock conversation is about XOMA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Apr 27

Ligand Pharmaceuticals ($LGND) is acquiring XOMA Royalty Corporation ($XOMA) for approximately $739 million in cash, with XOMA shareholders receiving $39 per share.
The deal will add seven commercial products to Ligand's royalty portfolio, as well as over 120 commercial, clinical, and preclinical assets.
The acquisition will strengthen Ligand's position as a leading biopharma royalty aggregator and further accelerate its profit growth.

Generated by AI

Sentiment

Of the messages about XOMA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% new	92.62% +16.35
Bearish	—	—	0% -100	7.38% -16.35

Bullish· Sep 6

XOMA has shown significant price gains, increasing by 147% since the S&P 500, with a 45% increase in the past day alone.
The company has a low float and a high number of short positions, indicating potential for further price appreciation.
XOMA has received an analyst upgrade to a "Buy" recommendation, suggesting increased confidence in the company's prospects.

Bearish· Mar 8

$XOMA's recent price drop may be due to a $300M shelf offering.
The company's earnings have been unimpressive, with a forecast EPS downgraded to a loss of $-0.42.
$XOMA's price has reached a 100% Fibonacci retracement from its 52-week high, indicating a potential reversal.

Generated by AI

Topics

Of the messages about XOMA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	93.84%
Analysts	—	—	—	2.05%
Controversies	—	—	—	3.23%
Earnings	—	—	—	0.29%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0.59%

Earnings· Mar 9

$XOMA reported Q4 earnings of 21 cents per share, beating analysts' expectations of a 15 cents per share loss.
Revenue was $48.18M, a 1007.6% year-over-year increase that also exceeded expectations.
The company's earnings beat estimate by 36 cents per share and revenue estimate by $44.17M.

Analysts· Sep 5

Wedbush upgraded XOMA Royalty Corp. from Neutral to Outperform with a price target of $19.00.
The price target was raised from $9.00, indicating a significant increase in the analyst's confidence in the company's prospects.
The upgrade is attributed to a pact with Novartis, which validates XOMA's new business model, according to the analyst.

Announcements· Apr 27

Ligand Pharmaceuticals ($LGND) is acquiring XOMA Royalty ($XOMA) in an all-cash deal worth approximately $740 million, or $39 per share.
The acquisition adds royalty exposure to over 120 drugs and expands Ligand's total portfolio to more than 200 medicines and pipeline assets.
XOMA Royalty stockholders will receive $39 per share in cash, representing a premium of 2.9% from the stock's last close, and one non-transferable CVR per share.

Technical Analysis· Mar 10

A MACD buy signal has been triggered on the daily and weekly charts for $XOMA.
$XOMA has formed a base and is expected to continue upwards, with a potential retest of the low.
The chart for $XOMA is showing a reverse head and shoulders pattern, with a potential break above $1.10.

Generated by AI

Community

Of the messages about XOMA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	40%	29.83%
Newcomers	—	—	60%	70.17%

Regulars· Sep 24

The regulars are comparing $XOMA to $TSLA, stating that XOMA has a stronger short-term outlook, with the potential for $TSLA to drop below $300.
Major shareholders, including Value Fund L.P. and Bvf Partners L.P./Il, are acquiring significant shares of XOMA Corp, with Value Fund L.P. buying 51,368 shares and Bvf Partners L.P./Il acquiring 22,328 shares.
The regulars are noting insider buying activity, with a director of XOMA Corp buying 17,089 shares, and one of the regulars estimating that the company's value has a negative long-term outlook.

Newcomers· Apr 27

The buyout of XOMA Royalty Corp. by Ligand Pharmaceuticals is a significant deal, with Ligand agreeing to pay $39 per share for the company, totaling $740 million.
Newcomers to XOMA are treating the stock as a "lotto play" due to its potential for a 5x increase, but also considering it a high-risk investment due to its low price.
The acquisition of XOMA by Ligand is expected to further accelerate profit growth and strengthen Ligand's position as a leading biopharma royalty aggregator, with the deal providing Ligand with royalty exposure to over 120 assets.

Generated by AI

XOMA

Social

Apr 27

Bullish· Sep 6

Bearish· Mar 8

Earnings· Mar 9

Analysts· Sep 5

Announcements· Apr 27

Technical Analysis· Mar 10

Regulars· Sep 24

Newcomers· Apr 27

Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book

LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline

Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital

LGND: XOMA Acquisition Closed

Stifel raises Ligand Pharma stock price target on Xoma acquisition

Ligand earnings on deck: Can XOMA deal deliver on promise?

Also Discussed

XOMA Corporation

Company Information

Location

Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book

LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline

Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital

LGND: XOMA Acquisition Closed

Stifel raises Ligand Pharma stock price target on Xoma acquisition

Ligand earnings on deck: Can XOMA deal deliver on promise?

Also Discussed

Social

Apr 27

Bullish· Sep 6

Bearish· Mar 8

Earnings· Mar 9

Analysts· Sep 5

Announcements· Apr 27

Technical Analysis· Mar 10

Regulars· Sep 24

Newcomers· Apr 27